Johnson & Johnson Trading Volume Drops 24% Ranking 92nd in Daily Volume

On June 5, 2025, Johnson & Johnson (JNJ) saw a trading volume of $812 million, marking a 24.34% decrease from the previous day. The stock closed with a 0.29% increase, ranking 92nd in the day's trading volume.

Johnson & Johnson remains committed to its oncology division, boasting a robust pipeline of drugs aimed at treating cancer and other diseases. The company is exploring the use of Talvey and Tecvayli in lung cancer treatments, leveraging its experience in multiple myeloma to expand its lung cancer pipeline.

Johnson & Johnson's niraparib combination therapy has shown significant efficacy in delaying prostate cancer progression in patients with HRR-altered genes, as demonstrated by strong Phase III trial data. The AMPLITUDE trial revealed a 48% reduction in radiographic progression or death and a 56% delay in symptomatic progression among BRCA-altered mCSPC patients receiving the niraparib combination.

Despite higher rates of anemia and hypertension, the combination's tolerability and improved outcomes support its earlier use in HRR-altered and BRCA-positive mCSPC patients, addressing a major unmet need in high-risk populations. The trial's primary endpoint was radiographic progression-free survival (rPFS), with the niraparib combination demonstrating a statistically significant and clinically meaningful improvement in rPFS and time to symptomatic progression.

Johnson & Johnson's Monarch robotics-assisted bronchoscopy system offers a minimally invasive alternative for lung cancer biopsies, reaching deep into the lungs for precise tissue sampling. This advanced technology enhances diagnostic capabilities and improves patient outcomes by providing a safer and more effective method for lung cancer detection and treatment.